Federal IDR outcomes in Arkansas
In 2025 Q1–Q4, the provider or facility offer prevailed in 87.7% of 96,183 determined Federal IDR dispute line items for services provided in Arkansas. The median prevailing offer was 4.85x the QPA (25th–75th percentile 3.30x–12.32x; n = 91,910). The median time to a decision was 35 business days (n = 96,183).
Determined line items
96,183
2025 Q1–Q4 · 142 split decisions excluded
Provider win rate
87.7%
n = 96,183 · 2025 Q1–Q4
Median payment vs QPA
4.85x
middle half 3.30x–12.32x · n = 91,910 · 2025 Q1–Q4
Median days to decision
35
business days, from dispute initiation · n = 96,183 · 2025 Q1–Q4
Dollar amounts
Total awarded
$261.3M
sum of prevailing offers · n = 199,743 · 2025 Q1–Q4
Total QPA
$73.5M
sum of QPAs, same line items · n = 199,743 · 2025 Q1–Q4
Awarded above QPA
$187.8M
total awarded minus total QPA · n = 199,743 · 2025 Q1–Q4
Median award per line item
$568
mean $1,308 · n = 199,743 · 2025 Q1–Q4
Median QPA
$140
per line item · n = 199,743 · 2025 Q1–Q4
Award vs QPA, dollar-weighted
3.55x
total awarded ÷ total QPA · n = 199,743 · 2025 Q1–Q4
Dollar amounts come from the separate CMS “QPA and Offers” file: line items decided for the provider or the plan with a non-suppressed QPA and prevailing offer. That file cannot be joined to the line items above, so its n differs. Awarded = the prevailing (selected) offer; it is not a record of what was paid. State comes from the file’s geographic region; a metro area that spans states counts in each. How the dollar figures work
Dollar amounts by period
| Period | Line items with $ | Total awarded | Total QPA | Above QPA | Median award | Median QPA | Award ×QPA ($-weighted) |
|---|---|---|---|---|---|---|---|
| 2025 Q1–Q4 | 199,743 | $261.3M | $73.5M | $187.8M | $568 | $140 | 3.55x |
| 2024 Q3–Q4 | 63,896 | $63.3M | $21.2M | $42.1M | $378 | $131 | 2.99x |
| 2024 Q3–2025 Q4 | 263,639 | $324.6M | $94.7M | $229.9M | $516 | $137 | 3.43x |
| 2023 Q1–2024 Q2 | Not available (see methodology). | ||||||
From the CMS QPA and Offers file (see above). Award ×QPA here is total awarded ÷ total QPA, so large claims weigh more than in the per-line median ratio.
By period
| Period | Line items | Win % | Median ×QPA | 25th–75th | Ratio n | Median days |
|---|---|---|---|---|---|---|
| 2025 Q1–Q4 | 96,183 | 87.7% | 4.85x | 3.30x–12.32x | 91,910 | 35 |
| 2024 Q1–Q4 | 21,956 | 85.9% | 3.46x | 2.81x–4.85x | 17,920 | 75 |
| 2023 Q1–Q4 | 2,919 | 86.0% | 3.15x | 1.98x–3.90x | 2,711 | 71 |
| 2023 Q1–2025 Q4 | 121,058 | 87.3% | 4.41x | 3.07x–10.84x | 112,541 | not pooled |
Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.
By specialty in Arkansas
| Specialty group | Line items | Win % | Median ×QPA | Ratio n | Median days |
|---|---|---|---|---|---|
| Emergency medicine and emergency departments | 83,817 | 88.5% | 5.20x | 83,449 | 34 |
| Hospitals and facilities | 7,221 | 87.8% | 3.12x | 5,004 | 59 |
| Intraoperative neuromonitoring | 2,294 | 86.7% | 23.36x † | 1,190 | 33 |
| Anesthesiology | 1,209 | 76.3% | 3.57x | 958 | 34 |
| Not reported / unspecified | 796 | 25.9% | 1.20x | 469 | 35 |
| Neonatology | 409 | 83.6% | 3.53x | 409 | 112 |
| Internal and family medicine | 168 | 74.4% | 6.36x | 168 | 33.5 |
| Plastic and reconstructive surgery | 76 | 96.1% | 5.30x | 73 | 88 |
| Hospital medicine (hospitalists) | 74 | 87.8% | 2.78x | 74 | 24 |
| Radiology | 44 | 95.5% | 2.20x | 44 | 24 |
| Other / unclassified labels | 38 | 73.7% | 3.60x | 35 | 31.5 |
2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.
Most disputed CPT codes in Arkansas
| CPT code | Line items | Win % | Median ×QPA | Ratio n | Median days |
|---|---|---|---|---|---|
| 99284 Emergency department visit with moderate level of medical decision making | 20,039 | 90.2% | 3.79x | 19,863 | 34 |
| 99285 Emergency department visit with high level of medical decision making | 10,595 | 88.9% | 3.60x | 10,468 | 35 |
| 99283 Emergency department visit with low level of medical decision making | 6,282 | 89.1% | 4.72x | 6,250 | 33 |
| 96374 Injection of drug or substance into vein | 2,453 | 86.3% | 2.20x | 2,402 | 35 |
| 85027 Complete blood cell count (red cells, white blood cell, platelets), automated te | 2,428 | 85.3% | 22.54x † | 2,405 | 28 |
| 85025 Complete blood cell count (red cells, white blood cell, platelets), automated te | 2,141 | 88.1% | 21.53x † | 2,008 | 45 |
| 80053 Blood test, comprehensive group of blood chemicals | 2,113 | 85.9% | 28.20x † | 1,973 | 36 |
| 96375 Injection of additional new drug or substance into vein | 2,077 | 85.9% | 7.45x | 2,002 | 35 |
| 96361 Infusion into a vein for hydration, each additional hour | 1,880 | 86.5% | 9.00x | 1,850 | 33 |
| 81003 Automated urinalysis test | 1,748 | 85.9% | 12.15x | 1,711 | 34 |
| 83735 Magnesium level | 1,724 | 86.9% | 18.19x | 1,661 | 35 |
| 93005 Routine electrocardiogram (ECG) using at least 12 leads with tracing | 1,642 | 90.3% | 9.68x | 1,549 | 36 |
| 83605 Lactic acid level | 1,601 | 87.2% | 6.16x | 1,572 | 35 |
| 80069 Kidney function blood test panel | 1,403 | 87.2% | 9.22x | 1,402 | 35 |
| 84484 Troponin (protein) analysis, quantitative | 1,331 | 87.9% | 11.13x | 1,233 | 36 |
| 71046 X-ray of chest, 2 views | 1,301 | 90.0% | 17.30x | 1,295 | 35 |
| 96372 Injection of drug or substance under skin or into muscle | 1,279 | 87.3% | 5.22x | 1,249 | 34 |
| 74177 CT scan of abdomen and pelvis with contrast | 1,161 | 84.8% | 32.29x † | 1,131 | 34 |
| 82150 Amylase (enzyme) level | 1,047 | 84.7% | 31.89x † | 1,039 | 33 |
| 82977 Glutamyltransferase (liver enzyme) level | 979 | 84.8% | 10.56x | 979 | 34 |
| 99291 Critical care, first 30-74 minutes | 942 | 90.0% | 3.03x | 921 | 35 |
| 81025 Urine pregnancy test | 901 | 87.1% | 5.84x | 871 | 34 |
| 93010 Routine electrocardiogram (ECG) using at least 12 leads with interpretation and | 892 | 90.5% | 10.35x | 891 | 33 |
| 74176 CT scan of abdomen and pelvis without contrast | 844 | 86.6% | 26.90x † | 829 | 35 |
| 70450 CT scan head or brain without contrast | 770 | 87.5% | 25.89x † | 734 | 37 |
2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.
Payers with the most determined line items in Arkansas
Payer = health plan/issuer email domain reported by CMS, with the most common plan name for that domain. Some domains belong to vendors acting for plans.
| Payer (email domain) | Line items | Win % | Median ×QPA | Ratio n | Median days |
|---|---|---|---|---|---|
| CIGNA (multiplan.com) | 47,263 | 84.2% | 7.56x | 46,525 | 34 |
| UNITED HEALTHCARE (uhc.com) | 16,997 | 88.7% | 3.56x | 14,562 | 44 |
| UMR (clearhs.com) | 10,105 | 85.8% | 4.63x | 10,023 | 32 |
| AMBETTER (centene.com) | 8,407 | 97.8% | 6.47x | 7,979 | 30 |
| UMR (clearhealthcloud.com) | 4,256 | 93.4% | 3.17x | 4,193 | 38 |
| HMO PARTNERS DBA HEALTH ADVANTAGE (mgb.org) | 3,906 | 100.0% | 12.24x | 3,902 | 58 |
| AETNA (aetna.com) | 1,234 | 95.0% | 7.73x | 1,212 | 26 |
| CIGNA (cigna.com) | 547 | 90.1% | 3.28x | 541 | 33 |
| QUALCHOICE (qualchoice.com) | 499 | 91.6% | 14.47x | 481 | 29 |
| ANTHEM BLUE CROSS BLUE SHIELD (anthem.com) | 311 | 93.6% | 16.49x | 226 | 73 |
2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.
Dollar amounts by CPT code in Arkansas
| CPT code | Line items with $ | Total awarded | Median award | Median QPA | Award ×QPA |
|---|---|---|---|---|---|
| 99284 Emergency department visit with moderate level of medical decision making | 43,187 | $63.2M | $759 | $189 | 3.62x |
| 99285 Emergency department visit with high level of medical decision making | 26,241 | $55.1M | $1,336 | $293 | 2.67x |
| 99283 Emergency department visit with low level of medical decision making | 10,870 | $16.8M | $1,555 | $203 | 3.39x |
| 80053 Blood test, comprehensive group of blood chemicals | 6,846 | $4.0M | $649 | $65 | 6.88x |
| 85025 Complete blood cell count (red cells, white blood cell, platelets), automated te | 6,315 | $2.0M | $128 | $31 | 8.35x |
| 93005 Routine electrocardiogram (ECG) using at least 12 leads with tracing | 4,432 | $1.8M | $314 | $109 | 3.55x |
| 84484 Troponin (protein) analysis, quantitative | 4,087 | $1.2M | $241 | $58 | 4.15x |
| 85027 Complete blood cell count (red cells, white blood cell, platelets), automated te | 3,609 | $670,278 | $225 | $17 | 6.35x |
| 96374 Injection of drug or substance into vein | 3,253 | $1.8M | $454 | $206 | 1.73x |
| 83735 Magnesium level | 3,024 | $572,434 | $201 | $21 | 6.10x |
| 87804 Detection test by immunoassay with direct visual observation for influenza virus | 2,918 | $695,860 | $259 | $76 | 2.89x |
| 74177 CT scan of abdomen and pelvis with contrast | 2,641 | $19.5M | $6,283 | $873 | 5.82x |
| 96375 Injection of additional new drug or substance into vein | 2,462 | $1.1M | $308 | $80 | 4.07x |
| 96361 Infusion into a vein for hydration, each additional hour | 2,385 | $2.1M | $354 | $68 | 3.23x |
| 71045 X-ray of chest, 1 view | 2,371 | $821,491 | $280 | $103 | 3.10x |
| 81003 Automated urinalysis test | 2,358 | $391,047 | $194 | $15 | 7.27x |
| 81001 Manual urinalysis test with examination using microscope, automated | 2,242 | $264,169 | $134 | $20 | 4.87x |
| 96372 Injection of drug or substance under skin or into muscle | 2,124 | $1.1M | $328 | $111 | 2.77x |
| 70450 CT scan head or brain without contrast | 1,963 | $8.1M | $2,191 | $539 | 7.28x |
| 71046 X-ray of chest, 2 views | 1,795 | $1.6M | $1,198 | $123 | 5.76x |
| 83605 Lactic acid level | 1,764 | $286,237 | $101 | $16 | 5.06x |
| 99291 Critical care, first 30-74 minutes | 1,662 | $2.3M | $1,001 | $308 | 3.04x |
| 81025 Urine pregnancy test | 1,652 | $277,213 | $143 | $29 | 4.86x |
| 80048 Blood test, basic group of blood chemicals (Calcium, total) | 1,558 | $627,389 | $408 | $51 | 6.63x |
| 36415 Insertion of needle into vein for collection of blood sample | 1,406 | $86,670 | $29 | $9 | 1.89x |
2025 Q1–Q4 · CMS QPA and Offers file · rows with n ≥ 30 line items with dollar amounts · sorted by n · Award ×QPA = total awarded ÷ total QPA.
FAQ
What is the Federal IDR provider win rate for services provided in Arkansas?
In 2025 Q1–Q4, the provider or facility offer was selected in 87.7% of 96,183 determined dispute line items for services provided in Arkansas. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.
How do Federal IDR payments compare with the QPA for services provided in Arkansas?
In 2025 Q1–Q4, the median prevailing offer was 4.85x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 3.30x to 12.32x (n = 91,910 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.
How long do Federal IDR decisions take for services provided in Arkansas?
In 2025 Q1–Q4, the median was 35 business days (n = 96,183 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).
Arkansas figures count line items whose place of service was Arkansas. See methodology for caveats.